Ibrutinib + Pembrolizumab + Rituximab
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Central Nervous System Lymphoma
Conditions
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
Trial Timeline
Aug 1, 2020 → Jan 5, 2027
NCT ID
NCT04421560About Ibrutinib + Pembrolizumab + Rituximab
Ibrutinib + Pembrolizumab + Rituximab is a phase 1/2 stage product being developed by Merck for Primary Central Nervous System Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04421560. Target conditions include Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04421560 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Primary Central Nervous System Lymphoma